Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s335962
Abstract: Purpose The US Food and Drug Administration has recently granted accelerated approval of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib as treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious germline or…
read more here.
Keywords:
management;
rucaparib treatment;
treatment;
teaes ... See more keywords